William Phipps, MD
Family Medicine · Sutherland, VANPI 1285601260
Payments from drug & device makers
Across 161 payments — averaging $14.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$235
- GSK$217
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$183
- Johnson & Johnson$176
- Novo Nordisk$168
- Pfizer$157
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,28799%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $235 |
| GSK | 16 | $217 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $183 |
| Johnson & Johnson | 15 | $176 |
| Novo Nordisk | 11 | $168 |
| Pfizer | 16 | $157 |
| Novartis | 10 | $146 |
| Merck | 11 | $139 |
| Amgen | 8 | $131 |
| Lilly USA, LLC | 9 | $118 |
| EMD Serono, Inc. | 6 | $83 |
| Bayer | 4 | $62 |
| Boehringer Ingelheim | 3 | $56 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Shire North American Group Inc | 3 | $44 |
| Nalpropion Pharmaceuticals LLC | 2 | $44 |
| Avanir Pharmaceuticals, Inc. | 3 | $42 |
| AbbVie(2 entities) | 2 | $39 |
| Sanofi-aventis U.S. LLC | 3 | $35 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Ardelyx, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Valeritas, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $13 |
| Cequr Corporation | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,315 in reported general payments places this provider in the 75th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $63,707 |
| EliquisApixaban | 46 | $54,289 |
| JardianceEmpagliflozin | 37 | $50,208 |
| JanuviaSitagliptin Phosphate | 39 | $44,799 |
| TrulicityDulaglutide | 29 | $35,482 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $34,792 |
| OzempicSemaglutide | 26 | $25,990 |
| XareltoRivaroxaban | 16 | $24,648 |
| CreonLipase/Protease/Amylase | 11 | $21,251 |
| TrintellixVortioxetine Hydrobromide | 15 | $11,387 |
| VeozahFezolinetant | 12 | $6,493 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $6,329 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 49 | $5,700 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $4,627 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,532 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $139 | $79,59267 claims |
| GSKTrelegy Ellipta | $217 | $63,70766 claims |
| PfizerEliquis | $157 | $54,28946 claims |
| Boehringer IngelheimJardiance | $56 | $50,20837 claims |
| Lilly USA, LLCTrulicity | $118 | $35,48229 claims |
| Novo NordiskOzempic | $168 | $25,99026 claims |
| Johnson & JohnsonXarelto | $176 | $24,64816 claims |
| AbbVieCreon, Synthroid | $39 | $22,83950 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $15 | $11,38715 claims |
| AstraZenecaSymbicort | $235 | $4,53215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Sutherland
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
- Samir AbdelshaheedChesapeake$642K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.